p53 Mutations and Survival in Non-Small-Cell Lung Cancer
Author Information
Author(s): FJ Vega, P Iniesta, T Caldes, A Sanchez, JA López, C de Juan, E Diaz-Rubio, A Torres, JL Balibrea, M Benito
Primary Institution: Hospital Universitario San Carlos, Madrid, Spain
Hypothesis
Can specific mutations in the p53 gene be associated with poor clinical outcomes in non-small-cell lung cancer patients?
Conclusion
p53 exon 5 mutations correlate with poorer survival in non-small-cell lung cancer patients, especially in those with squamous cell tumors.
Supporting Evidence
- p53 protein was detected in 46.9% of lung carcinomas analyzed.
- 44.7% of p53-immunopositive tumors showed p53 mutations.
- Patients with p53 mutations had shorter survival compared to those without.
- Squamous cell carcinoma patients with p53 exon 5 mutations had the worst prognosis.
Takeaway
This study found that certain changes in a gene called p53 can help predict how long people with lung cancer might live.
Methodology
The study analyzed 81 lung cancer samples for p53 mutations using immunohistochemistry and sequencing techniques.
Limitations
The study only included patients who underwent surgery, which may not represent all lung cancer patients.
Participant Demographics
79 men and 2 women, median age 62.2 years.
Statistical Information
P-Value
0.007
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website